Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen

C. M. Vachon, J. N. Ingle, V. J. Suman, C. G. Scott, H. Gottardt, J. E. Olson, P. E. Goss

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

Breast density, a strong risk factor for breast cancer, is reduced by the anti-estrogen, tamoxifen (TAM). We examined whether aromatase inhibitor (AI) therapy results in further reductions in breast density among women completing 5 years of TAM. Among a sample of women with early-onset breast cancer who were randomized to letrozole (LET)(n=56) or placebo (PLAC)(n=48) after 5 years of TAM, we examine the change in percent density at 9-15 months as well as a per-year change in PD by treatment group. There was no difference in the adjusted mean change (-1.0%, LET; -0.3%, PLAC (P=0.58)) or the percentage change (-2.7%, LET; -3.0%, PLAC (P=0.96)) in PD between treatment groups at 9-15 months. Results were similar for longitudinal change (-0.68% per year, LET; -0.12% per year, PLAC (P=0.23)). Breast density does not appear to be a clinically relevant biomarker in women who already have low PD following 5 years of TAM. Crown

Original languageEnglish (US)
Pages (from-to)204-210
Number of pages7
JournalBreast
Volume16
Issue number2
DOIs
StatePublished - Apr 2007

Keywords

  • Aromatase inhibitors
  • Breast density
  • Mammographic density

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen'. Together they form a unique fingerprint.

  • Cite this